Aripiprazole, A Drug That Displays Partial Agonism and Functional Selectivity

Overview

Journal Curr Neuropharmacol

Publisher Bentham Science Publishers

Date 2017 Apr 18

PMID 28412910

Citations 33

Authors

Erin W Tuplin

Matthew R Holahan

Affiliations

Soon will be listed here.

Abstract

Background: The treatment of schizophrenia is challenging due to the wide range of symptoms (positive, negative, cognitive) associated with the disease. Typical antipsychotics that antagonize D2 receptors are effective in treating positive symptoms, but extrapyramidal side-effects (EPS) are a common occurrence. Atypical antipsychotics targeting 5-HT2A and D2 receptors are more effective at treating cognitive and negative symptoms compared to typical antipsychotics, but these drugs also result in side-effects such as metabolic syndromes.

Objective: To identify evidence in the literature that elucidates the pharmacological profile of aripiprazole.s.

Methods: We searched PubMed for peer reviewed articles on aripiprazole and its clinical efficacy, side-effects, pharmacology, and effects in animal models of schizophrenia symptoms.

Results: Aripiprazole is a newer atypical antipsychotic that displays a unique pharmacological profile, including partial D2 agonism and functionally selective properties. Aripiprazole is effective at treating the positive symptoms of schizophrenia and has the potential to treat negative and cognitive symptoms at least as well as other atypical antipsychotics. The drug has a favorable side-effect profile and has a low propensity to result in EPS or metabolic syndromes. Animal models of schizophrenia have been used to determine the efficacy of aripiprazole in symptom management. In these instances, aripiprazole resulted in the reversal of deficits in extinction, pre-pulse inhibition, and social withdrawal. Because aripiprazole requires a greater than 90% occupancy rate at D2 receptors to be clinically active and does not produce EPS, this suggests a functionally selective effect on intracellular signaling pathways.

Conclusion: A combination of factors such as dopamine system stabilization via partial agonism, functional selectivity at D2 receptors, and serotonin-dopamine system interaction may contribute to the ability of aripiprazole to successfully manage schizophrenia symptoms. This review examines these mechanisms of action to further clarify the pharmacological actions of aripiprazole.

Citing Articles

Optimising Aripiprazole Long-Acting Injectable: A Comparative Study of One- and Two-Injection Start Regimens in Schizophrenia with and Without Substance Use Disorders and Relationship to Early Serum Levels.

Trovini G, Lombardozzi G, Kotzalidis G, Lionetto L, Russo F, Sabatino A Int J Mol Sci. 2025; 26(3).

PMID: 39941162 PMC: 11818917. DOI: 10.3390/ijms26031394.

From Psychiatry to Oncology: Exploring the Anti-Neoplastic Mechanisms of Aripiprazole and Its Potential Use in Cancer Treatment.

OCallaghan L, Blum C, Powell K, Chess-Williams R, McDermott C Pharmacol Res Perspect. 2025; 13(1):e70076.

PMID: 39939172 PMC: 11821285. DOI: 10.1002/prp2.70076.

A systematic review and meta-analysis of the effects of combined aripiprazole on glycolipid metabolism in schizophrenia.

Wei T, Jiang L, Zhang R, Su H, Sun Z, Sun J Front Psychiatry. 2025; 15:1496986.

PMID: 39866685 PMC: 11757238. DOI: 10.3389/fpsyt.2024.1496986.

Aripiprazole-Induced Orofacial Dyskinesia in a Young Male: A Case Report.

Godhania U, Rajendran J, Odeyemi O Cureus. 2024; 16(11):e73269.

PMID: 39651025 PMC: 11625393. DOI: 10.7759/cureus.73269.

Myosin VI drives arrestin-independent internalization and signaling of GPCRs.

Patel N, Ripoll L, Peach C, Ma N, Blythe E, Vaidehi N Nat Commun. 2024; 15(1):10636.

PMID: 39638791 PMC: 11621365. DOI: 10.1038/s41467-024-55053-9.

References

Casey D, Carson W, Saha A, Liebeskind A, Ali M, Jody D . Switching patients to aripiprazole from other antipsychotic agents: a multicenter randomized study. Psychopharmacology (Berl). 2003; 166(4):391-9. DOI: 10.1007/s00213-002-1344-3. View

Meltzer H, Stahl S . The dopamine hypothesis of schizophrenia: a review. Schizophr Bull. 1976; 2(1):19-76. DOI: 10.1093/schbul/2.1.19. View

Angermeyer M, Kuhn L . Gender differences in age at onset of schizophrenia. An overview. Eur Arch Psychiatry Neurol Sci. 1988; 237(6):351-64. DOI: 10.1007/BF00380979. View

Jakab R, Goldman-Rakic P . 5-Hydroxytryptamine2A serotonin receptors in the primate cerebral cortex: possible site of action of hallucinogenic and antipsychotic drugs in pyramidal cell apical dendrites. Proc Natl Acad Sci U S A. 1998; 95(2):735-40. PMC: 18490. DOI: 10.1073/pnas.95.2.735. View

Mallikaarjun S, Salazar D, Bramer S . Pharmacokinetics, tolerability, and safety of aripiprazole following multiple oral dosing in normal healthy volunteers. J Clin Pharmacol. 2004; 44(2):179-87. DOI: 10.1177/0091270003261901. View

Keefe R, Bilder R, Davis S, Harvey P, Palmer B, Gold J . Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial. Arch Gen Psychiatry. 2007; 64(6):633-47. DOI: 10.1001/archpsyc.64.6.633. View

Amato D . Serotonin in antipsychotic drugs action. Behav Brain Res. 2014; 277:125-35. DOI: 10.1016/j.bbr.2014.07.025. View

Reichenberg A . The assessment of neuropsychological functioning in schizophrenia. Dialogues Clin Neurosci. 2010; 12(3):383-92. PMC: 3181984. View

Meltzer H, McGurk S . The effects of clozapine, risperidone, and olanzapine on cognitive function in schizophrenia. Schizophr Bull. 1999; 25(2):233-55. DOI: 10.1093/oxfordjournals.schbul.a033376. View

10.

Zhang J, Chiodo L, Freeman A . Electrophysiological effects of MK-801 on rat nigrostriatal and mesoaccumbal dopaminergic neurons. Brain Res. 1992; 590(1-2):153-63. DOI: 10.1016/0006-8993(92)91091-r. View

11.

Giros B, Sokoloff P, Martres M, Riou J, Emorine L, Schwartz J . Alternative splicing directs the expression of two D2 dopamine receptor isoforms. Nature. 1989; 342(6252):923-6. DOI: 10.1038/342923a0. View

12.

Kirschbaum K, Muller M, Malevani J, Mobascher A, Burchardt C, Piel M . Serum levels of aripiprazole and dehydroaripiprazole, clinical response and side effects. World J Biol Psychiatry. 2007; 9(3):212-8. DOI: 10.1080/15622970701361255. View

13.

Usiello A, Baik J, Rouge-Pont F, Picetti R, Dierich A, Lemeur M . Distinct functions of the two isoforms of dopamine D2 receptors. Nature. 2000; 408(6809):199-203. DOI: 10.1038/35041572. View

14.

DeLeon A, Patel N, Crismon M . Aripiprazole: a comprehensive review of its pharmacology, clinical efficacy, and tolerability. Clin Ther. 2004; 26(5):649-66. DOI: 10.1016/s0149-2918(04)90066-5. View

15.

Kern R, Green M, Cornblatt B, Randall Owen J, McQuade R, Carson W . The neurocognitive effects of aripiprazole: an open-label comparison with olanzapine. Psychopharmacology (Berl). 2006; 187(3):312-20. DOI: 10.1007/s00213-006-0428-x. View

16.

Brust T, Hayes M, Roman D, Watts V . New functional activity of aripiprazole revealed: Robust antagonism of D2 dopamine receptor-stimulated Gβγ signaling. Biochem Pharmacol. 2014; 93(1):85-91. PMC: 4276521. DOI: 10.1016/j.bcp.2014.10.014. View

17.

Li Y, Gao W . GSK-3β activity and hyperdopamine-dependent behaviors. Neurosci Biobehav Rev. 2010; 35(3):645-54. PMC: 2997336. DOI: 10.1016/j.neubiorev.2010.08.001. View

18.

Tandon R, Jibson M . Extrapyramidal side effects of antipsychotic treatment: scope of problem and impact on outcome. Ann Clin Psychiatry. 2002; 14(2):123-9. DOI: 10.1023/a:1016811222688. View

19.

Tadokoro S, Okamura N, Sekine Y, Kanahara N, Hashimoto K, Iyo M . Chronic treatment with aripiprazole prevents development of dopamine supersensitivity and potentially supersensitivity psychosis. Schizophr Bull. 2011; 38(5):1012-20. PMC: 3446226. DOI: 10.1093/schbul/sbr006. View

20.

Yee B, Singer P . A conceptual and practical guide to the behavioural evaluation of animal models of the symptomatology and therapy of schizophrenia. Cell Tissue Res. 2013; 354(1):221-46. PMC: 3791321. DOI: 10.1007/s00441-013-1611-0. View